

**Editorial Board ID: 00058511**

Thessaloniki

December 6, 2023

Dr. Lian-Sheng Ma

Founder and Chief Executive Officer

Baishideng Publishing Group, Inc.

Dear Editor:

Thank you for your preliminary decision regarding our invited paper entitled "Management of obstructed colorectal carcinoma in an emergency setting: An update" (Manuscript NO: 89058), which was sent to the *World Journal of Gastrointestinal Oncology* for publication as a *Review*.

I would like to thank the reviewers for their earnest efforts in reviewing the manuscript. I have accepted all considerations expressed by the reviewers for improving the manuscript and have responded to them step by step. The changes are highlighted in yellow.

#### **Reviewer 1**

Many thanks for your considerable comments. Your concise review is very much appreciated.

1. As suggested, the Figure 2 has been revised including the clinical indications for each kind of management choice.

2. The general considerations of surgical management include all the aspects expressed around this topic, which are discussed in detail. What should be kept in mind is clearly seen in the conclusions section and also in the Core tip.

3. No, there are not. Thus, it has been added the following text "*restricting any potential unwilling effect of stent application [72]. It seems reasonable, but there are not survival data supporting this choice.*" (page 11, lines 11-13).

4. As suggested, some data of Table 1 have been refined in the text by adding a. "*a perforation rate of 13% and migration, occlusion rate of 2.9%*" (page 13, lines 1-2), b.

*“bowel perforation (1.4%), stent migration (0.5%), stent detachment (0.7%) and stool impaction (1.4%)”* (page 13, lines 17-18), c. *“and clinical success rate of 92.8%; and migration, occlusion rate of 1.3%”* (page 14, lines 27-28).

5. As suggested, specific data have been presented in Table 2 and 3.

6. As suggested, an additional Table 4 summarizing the advantages and disadvantages of tubing and stenting has been created.

7. As suggested, the references 114, 117 have been deleted.

## **Reviewer 2**

No comments. Thank you.

## **Reviewer 3**

Many thanks for your positive comments.

1. The Figure 2 has been revised as suggested including the clinical indications for each kind of management choice.

I am sending the revised manuscript and hope to receive a favorable final decision.

We look forward to hearing from you at your earliest convenience.

Sincerely,

Theodoros E Pavlidis MD, PhD

Emeritus Professor of Surgery

School of Medicine

Aristotle University of Thessaloniki Greece

Hippocraton Hospital, Konstantinoupoleos 49, 546 42

2<sup>nd</sup> Surgical Propedeutic Department

e-mail: [pavlidth@auth.gr](mailto:pavlidth@auth.gr)

**Editorial Board ID: 00058511**